Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company committed to developing novel small-molecule therapeutics designed to restore neuronal health and slow the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Their scientific approach focuses on positively modulating the HGF/MET neurotrophic system, a key pathway in brain function and repair. Athira's lead product candidate, fosgonimeton (ATH-1017), aims to impact neurodegeneration and improve cognitive function by enhancing this system.
The headquarters serves as the primary center for Athira Pharma's research and development activities, clinical operations management, and corporate administrative functions, guiding the company's strategic initiatives.
Situated within a modern business park tailored to technology and life science companies, the facility likely includes specialized laboratory spaces and office environments designed to support biopharmaceutical innovation. Specific architectural highlights are not publicly emphasized.
The work culture at Athira Pharma's headquarters is expected to be highly collaborative, scientifically rigorous, and patient-focused, characteristic of a biopharmaceutical company tackling complex neurological disorders. There's likely a strong emphasis on innovation, teamwork, and ethical research practices.
The Bothell headquarters is pivotal for Athira, leveraging the region's rich talent pool in biotechnology and its robust infrastructure for life sciences research. It's the command center for their global clinical trial efforts and R&D pipeline.
Athira Pharma's global presence is primarily defined by its international clinical trial operations. To ensure diverse patient populations and robust data for its drug development programs, the company engages with clinical research sites and investigators in North America, Europe, and potentially other regions. While its corporate and primary research functions are centralized in the U.S., its mission to address neurodegenerative diseases has a worldwide scope through these clinical studies and potential future partnerships.
18706 North Creek Parkway, Suite 104
Bothell
WA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Athira Pharma' leadership includes:
Athira Pharma has been backed by several prominent investors over the years, including:
Over the past 12-18 months, Athira Pharma has made significant updates to its executive team, including appointing a new Chief Financial Officer in mid-2023, and a new Chief Business Officer and Chief Scientific Officer in late 2023 and early 2024, respectively. These changes aim to strengthen leadership for its ongoing clinical development and strategic growth.
Discover the tools Athira Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Athira Pharma likely uses standard corporate email address formats. The most common pattern observed for companies of similar size and industry is the first initial followed by the last name.
flast@athira.com (e.g., jdoe@athira.com)
Format
example@athira.com
Example
85%
Success rate
GlobeNewswire • May 16, 2024
Athira Pharma announced the enrollment of the first patient in its LIFT-AD Open Label Extension (OLE) study. This study is designed to evaluate the long-term safety and tolerability of fosgonimeton in patients with mild-to-moderate Alzheimer's disease who previously completed the LIFT-AD Phase 2/3 trial....more
GlobeNewswire • May 9, 2024
Athira Pharma reported its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical development pipeline. Key highlights included progress in the LIFT-AD study for Alzheimer's disease and the SHAPE-PD study for Parkinson's disease dementia or Lewy body dementia....more
GlobeNewswire • February 29, 2024
Athira Pharma announced its financial results for the full year ended December 31, 2023, and offered updates on its pipeline, including ongoing clinical trials for fosgonimeton in neurodegenerative diseases. The company highlighted its strategic priorities for advancing its therapeutic candidates....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Athira Pharma, are just a search away.